NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients

Area of Science:

• Oncology
• Molecular Biology
• Biomarkers

Background:

• Soft-tissue sarcoma (STS) poses significant clinical challenges, with postsurgical recurrence and metastasis being major concerns.
• Identifying reliable prognostic markers is crucial for improving patient outcomes and treatment strategies.

Purpose of the Study:

• To investigate the prognostic value of NG2 proteoglycan expression in soft-tissue sarcoma.
• To determine if NG2 levels can predict the risk of postsurgical secondary lesions and metastasis.

Main Methods:

• Analysis of NG2 proteoglycan expression levels in presurgical primary STS lesions.
• Evaluation of NG2 transcription levels in both primary and metastatic STS lesions.
• Correlation of NG2 expression with clinical outcomes, including secondary lesion development and metastasis timing.

Main Results:

• Enhanced NG2 proteoglycan expression in primary STS lesions predicted a 55% probability of secondary lesions within 12 months post-surgery.
• NG2 transcription was amplified 81-fold in metastatic lesions compared to primary ones.
• Higher NG2 levels in both primary and metastatic lesions correlated with a significantly poorer clinical course.
• Multivariate analysis confirmed NG2 upregulation as an independent prognostic parameter.

Conclusions:

• NG2 proteoglycan is a potent molecular predictor of early postsurgical recurrence in STS.
• Assessment of NG2 gene transcription offers a minimally invasive method to predict metastatic disease and define life expectancy in STS patients.
• NG2 expression serves as a critical biomarker for stratifying STS patient risk and guiding clinical management.